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Abstract
Background: Recent studies have suggested that mast-cell activation and inflammation are important in obesity and
diabetes. Plasma levels of mast cell proteases and the mast cell activator immunoglobulin E (IgE) may serve as novel
inflammatory markers that associate with the risk of pre-diabetes and diabetes mellitus.
Methods and Results: A total of 340 subjects 55 to 75 years of age were grouped according to the American Diabetes
Association 2003 criteria of normal glucose tolerance, pre-diabetes, and diabetes mellitus. The Kruskal-Wallis test
demonstrated significant differences in plasma IgE levels (P=0.008) among groups with different glucose tolerance status.
Linear regression analysis revealed significant correlations between plasma levels of chymase (P=0.030) or IgE (P=0.022)
and diabetes mellitus. Ordinal logistic regression analysis showed that IgE was a significant risk factor of pre-diabetes and
diabetes mellitus (odds ratio [OR]: 1.674, P=0.034). After adjustment for common diabetes risk factors, including age, sex,
hypertension, body-mass index, cholesterol, homeostatic model assessment (HOMA) index, high-sensitivity C-reactive
protein (hs-CRP), and mast cell chymase and tryptase, IgE remained a significant risk factor (OR: 1.866, P=0.015). Two-
variable ordinal logistic analysis indicated that interactions between hs-CRP and IgE, or between IgE and chymase, increased
further the risks of developing pre-diabetes and diabetes mellitus before (OR: 2.204, P=0.044; OR: 2.479, P=0.033) and after
(OR: 2.251, P=0.040; OR: 2.594, P=0.026) adjustment for common diabetes risk factors.
Conclusions: Both IgE and chymase associate with diabetes status. While IgE and hs-CRP are individual risk factors of pre-
diabetes and diabetes mellitus, interactions of IgE with hs-CRP or with chymase further increased the risk of pre-diabetes
and diabetes mellitus.
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Introduction
The development of diabetes mellitus — and in particular, of
type 2 diabetes mellitus (type 2 DM) — involves multiple stages
and is complicated by multiple factors, such as obesity and
cardiovascular disease. The exact mechanisms leading to diabetes
mellitus, however, remain unknown. Pre-diabetes refers to the
intermediate states between normal glucose tolerance (NGT) and
type 2 DM and is the precursor of type 2 DM. Individuals with
pre-diabetes often bear clusters of cardiovascular disease risk
factors [1]. In recent years, studies have focused on the
inflammatory risk factors of pre-diabetes and type 2 DM [1–6].
Elevated plasma levels of inflammatory high-sensitivity C-reactive
protein (hs-CRP) were seen in two Asian-population–based
cohorts of pre-diabetes [7]. Mast cells are essential components
of asthma and allergic responses [8,9], but recent studies have
shown that these cells are important in diet-induced obesity and
type 2 DM. Mice lacking mast cells or receiving the mast cell
inhibitors cromolyn or ketotifen (Zaditor) are fully protected from
developing type 2 DM [10]. By releasing the mast-cell–specific
serine proteases chymase [11] and trypase [12], these ‘‘allergy
cells’’ contribute to neovascularization and vascular-cell apoptosis.
One of the best-known mechanisms of mast cell activation is the
binding of immunoglobulin E (IgE) to its high-affinity receptor
FceR1 on the mast cell surface. After IgE binding, mast cells
release histamine, mast cell protease, proteoglycan, cytokines, and
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28962chemokines [13,14]. Many of these inflammatory mediators
associate with diabetes mellitus [15–17]. Plasma levels of mast
cell chymase and tryptase are greatly elevated in patients with
acute myocardial infarction (AMI) or unstable angina pectoris
(UAP) [18]. We recently showed that human plasma IgE levels
also associate with coronary artery intima thickness and rupture.
IgE levels in patients with AMI were double those in subjects with
stable angina pectoris (SAP) or without coronary heart disease
(CHD) [19]. In human atherosclerotic lesions, IgE and its receptor
FceR1 are localized to macrophage-rich areas, as well as to
smooth-muscle cells (SMCs) and endothelial cells (ECs). In
atherosclerosis-prone apolipoprotein E–deficient (Apoe
2/2) mice,
the absence of FceR1 a-subunit reduced atherosclerotic lesion
sizes by 75% in the thoracic to abdominal aorta, and by more than
50% in the aortic arch. Mechanistically, we demonstrated that IgE
activated macrophage, EC, and SMC signaling transduction,
apoptosis, and cytokine and chemokine production [19] — all of
which participate in metabolic diseases [10,20,21]. The current
study is designed to examine whether IgE and mast cell proteases
associate with infammation and diabetes status in a Chinese
population from a pre-diabetes study.
Materials and Methods
Study population
This study is part of the Pre-diabetes Intervention Project
(PDIP), which began in 2008 at the School of Medicine, Huzhou
Teacher’s College, Zhejiang, China. From July to August 2008, a
total of 3163 volunteers 55 to 75 years of age, from three
neighborhood communities in the city of Huzhou, were invited for
pre-diabetes screening. After excluding subjects with known DM
or cardiovascular disease, cerebrovascular disease, malignant
disease, chronic liver disease, or kidney failure, and those taking
medications, 1500 volunteers were invited for a fasting glucose test
and a 2-hour oral glucose tolerance test (2h-OGTT) as part of the
pre-diabetes screening. Of those, 1197 accepted the invitation and
participated in both tests from September to December 2008.
Among the subjects, 807 (67.42%) had normal glucose tolerance
(NGT), 267 (22.30%) were diagnosed with pre-diabetes, and 123
(10.28%) were diagnosed with DM. One year after the initial visit,
267 pre-diabetes subjects, 123 DM subjects, and 100 randomly-
selected NGT subjects were invited for anthropometric measure-
ments and clinical tests. A total of 340 subjects participated in the
final study, and among them, 71 had normal glucose tolerance
(NGT), 189 had pre-diabetes, and 80 had DM. This study was
approved by the Huzhou City Ethics Committee, and all subjects
gave written, informed consent prior to participating.
Data collection
Demographic data, including age and sex, were collected at the
registry. Anthropometric measurements (body height and weight,
waist and hip circumference) were performed with the subjects
wearing light underwear and without shoes. The biochemical
parameters were measured in the Clinical Biochemistry Unit of
Huzhou First Hospital, a teaching hospital of the School of
Medicine. All participants were fasted for 10–12 hours to
determine plasma glucose levels, lipid profiles, and insulin levels.
To perform 2h-OGTT, participants were asked not to smoke or to
partake in vigorous exercise during 2 hours of sample collection,
and rested for a minimum of 15 minutes. An antecubital blood
sample was drawn immediately before and 2 hours after glucose
ingestion. The glucose oxidase method was used (Japanese
OLYMPUS AV640 Automatic Biochemical Analyzer) to measure
plasma glucose concentration. Plasma hs-CRP levels were
determined by a high-sensitivity latex-enhanced nephelometric
assay (Sysmex Wuxi Co., Ltd., Wuxi, China). Plasma insulin
(Abbott Japan Co., Ltd., Tokyo, Japan) and IgE (DiaSys
Diagnostic Systems GmbH, Holzheim, Germany) levels were
measured using a radioimmunoassay. Plasma total cholesterol
(TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-
C), and high-density lipoprotein cholesterol (HDL-C) were
determined by an enzymatic assay (Beijing Leadman Biochemistry
Co., Ltd., Beijing, China). Plasma chymase and tryptase levels
were determined as described previously [18].
Clinical criteria
Subjects with diabetes and pre-diabetes were grouped according
to American Diabetes Association 2003 criteria [22]. Diabetes was
classified with a fasting plasma glucose (FPG) $7.0 mmol/L or
2h-OGTT $11.1 mmol/L, or receiving hypoglycemic medica-
tion; whereas pre-diabetes was defined as FPG $5.6 and
,7.0 mmol/L or 2h-OGTT $7.8 and ,11.1 mmol/L. Subjects
were classified as having a normal glucose profile if FPG
,5.6 mmol/L and 2h-OGTT ,7.8 mmol/L.
Based on China 2006 Blood Pressure Control Criteria and
China Prevention and Treatment Classification Recommendation
on Dyslipidemia [23], hypertension was defined as systolic blood
pressure (SBP) and/or diastolic blood pressure (DBP) $140/
90 mmHg, or as receiving blood-pressure–lowering medications;
high TG was defined as a fasting plasma TG $1.70 mmol/L, low
HDL-C as a fasting HDL-C #0.9 mmol/L, high TC as TC
$5.72 mmol/L, and low LDL-C as a fasting LDL-C
#3.64 mmol/L. Based on the China Obesity Task Group
Recommendation [24], general obesity was classified as body-
mass index (BMI) $24 kg/m
2; central obesity was defined as a
waist circumference (WC) $80 cm in females or 85 cm in males.
High waist-to-hip ratio (WHR) was classified as normal/abnormal
according to upper quartile (P75=0.93). Homeostatic model
assessment–insulin resistance (HOMA-IR=value of FPG 6value
of fasting insulin/22.5) was classified as normal/abnormal
according to upper quartile (P75=2.58), and HOMA-b cell
function [HOMA-b=20 6 value of fasting insulin/(FPG-3.5)]
was classified as normal/abnormal according to bottom quartile
(P25=38.17). Hyperinsulinemia was classified as normal/abnor-
mal according to upper quartile (P75=9.38 mIU/L).
Statistical analysis
We used the mean and standard deviation of continuous and
normal distributional variables and the median and interquartile
range of continuous but skewed distributional variables. Data were
analyzed using one-way analysis of variance (ANOVA), chi-square
test, linear regression test, Kruskal-Wallis test, ordinal logistic
model, or binary logistic model. All statistical analyses were
conducted using SPSS statistical software (version 11.0).
Results
Population distribution
Basic characteristics of all 340 participants are shown in Table 1.
All data with normal distributions were expressed as mean 6 SD
(standard deviation); otherwise, data were expressed as median
and interquartile ranges. Sex was expressed as the percentage of
males, and plasma tryptase levels were expressed as percentages of
those among the upper quartile (.2.74 ng/mL). Of the 340
participants — 96 men (average age, 67.8465.35 years) and 244
women (average age, 64.3066.02 years) — 71 (20.9%) were
classified as NGT subjects, 189 (55.6%) as pre-diabetes subjects,
and 80 (23.6%) as diabetes subjects. One-way ANOVA, Kruskal-
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HOMA-b, HOMA-IR, TG, WC, AC, WHR, hs-CRP, and IgE
levels were significantly higher in patients with pre-diabetes or
diabetes mellitus than in the normal glucose group (NGG).
Compared with patients in the NGG, levels of FPG, 2h-OGTT,
fasting insulin, HOMA-b, HOMA-IR, SBP, WHR, hs-CRP, and
IgE were significantly higher in the pre-diabetes group (PDG);
levels of FPG, 2h-OGTT, fasting insulin, HOMA-b, HOMA-IR,
TC, TG, BMI, WC, AC, WHR, hs-CRP, IgE, and chymase also
were significantly higher in the diabetes mellitus group (DMG)
(Table 1). Linear regression analysis revealed significant correla-
tions in levels of FPG, 2h-OGTT, fasting insulin, HOMA-b,
HOMA-IR, TC, TG, HDL-C, BMI, WC, AC, WHR, IgE, and
chymase among the NGG, PDG, and DMG (Table 1).
Plasma IgE, chymase, and tryptase as independent risk
factors of pre-diabetes and diabetes mellitus
Ordinal logistic regression analysis examined whether IgE and
mast cell protease chymase and tryptase are significant risk factors
for pre-diabetes and diabetes mellitus in this Chinese population,
compared with variables from the NGG. Four different models of
adjustment were used, based on selections of similar variables:
Models one and three used HOMA-IR, whereas models two and
four used HOMA-b. Models one and two used WC as the obesity
standard, whereas models three and four used BMI (Table 2).
Before adjustment for any of the variables listed in Table 2,
hypertension, WC, WHR, HOMA-IR, HOMA-b, hs-CRP, and
IgE were significant risk factors for pre-diabetes and diabetes
mellitus. After adjustment in all four models, however, only
hypertension and HOMA-IR (or HOMA-b) remained significant
risk factors for pre-diabetes and diabetes mellitus. Among the
remaining variables, IgE remained a significant pre-diabetes and
diabetes mellitus risk factor in three models of adjustment. In
contrast, mast cell chymase and tryptase were not significant risk
factors for pre-diabetes and diabetes mellitus before or after
adjustment for all common diabetes variables (Table 2).
Binary logistic regression analysis allowed us to examine risk
factors for either pre-diabetes or diabetes mellitus, compared with
variables from the NGG. Before adjustment, hypertension, WC,
WHR, hs-CRP, and IgE were significant risk factors for pre-
diabetes, while high hypertension, WC, WHR, BMI, HOMA-b
index, HOMA-IR index, and hs-CRP levels were significant risk
Table 1. Biochemical and anthropometric parameters in 340 subjects with different glucose status, grouped according to fasting
and post-load glucose levels.
Variable NGG (n=71) PDG (n=189) DMG (n=80) P value
d P value
e
Age (years)
a 65.1366.17 65.4966.20 65.0065.23 0.875 0.875
Sex (%, male)
b 21.1 31.7 26.3 0.533 0.533
FPG (mmol/L)
c 4.98 (4.60–5.19) 5.76 (5.53–6.04){ 6.73 (6.24–7.58){ ,0.001 ,0.001
2h-OGTT (mmol/L)
a 5.5061.25 7.2761.29{ 13.4461.33{ ,0.001 ,0.001
Fasting insulin (mU/L)
a 5.4261.82 6.4161.70{ 6.5061.75{ 0.169 0.049
HOMA-b
a 88.1362.54 62.5162.42{ 42.4763.05{ ,0.001 ,0.001
HOMA-IR
c 1.14 (0.75–1.88) 1.65 (1.20–2.34){ 1.86 (1.41–2.91){ ,0.001 ,0.001
SBP (mmHg)
a 134.00615.89 139.37617.54{ 139.87621.93 0.080 0.057
DBP (mmHg)
a 77.9367.41 79.0369.40 78.78610.80 0.7000 0.595
TC (mmol/L)
a 4.8760.97 5.0461.05 5.2060.96{ 0.136 0.046
TG (mmol/L)
c 1.22 (0.79–1.79) 1.46 (1.01–1.98) 1.63 (1.20–2.36){ 0.005 0.037
HDL-C (mmol/L)
c 1.23 (1.06–1.42) 1.20 (1.05–1.37) 1.16 (0.99–1.35) 0.257 0.030
LDL-C (mmol/L)
c 2.43 (2.04–3.00) 2.47 (2.11–2.98) 2.58 (2.18–3.00) 0.455 0.234
BMI (kg/m
2)
a 23.5263.39 24.2963.38 24.7663.14{ 0.073 0.024
WC (cm)
a 79.8868.61 83.5268.85{ 83.53610.93{ 0.015 0.021
AC (cm)
a 90.7967.58 92.7467.46 93.9466.81{ 0.033 0.010
WHR
c 0.87 (0.83–0.90) 0.89 (0.86–0.93){ 0.90 (0.87–0.95){ ,0.001 0.002
hs-CRP (mg/dL)
c 2.00 (1.00–3.00) 5.00 (3.00–8.80){ 5.00 (3.00–8.00){ ,0.001 0.475
IgE (IU/L)
c 9.00 (4.00–26.00) 16.00 (5.00–55.50){ 25.00 (7.00–72.50){ 0.008 0.022
Chymase (ug/ml)
c 18.17 (12.37–25.28) 20.91 (13.30–26.61) 23.05 (14.52–26.61){ 0.083 0.030
Tryptase (%, .2.74 ng/ml)
b 22.1 24.1 30.4 0.573 0.208
NGG: normal glucose group; PDG: pre-diabetes group; DMG: diabetes mellitus group; FPG: fasting plasma glucose; 2h-OGTT: 2-hour oral glucose tolerance test; BMI:
body-mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WC: waist circumference; AC: abdominal circumference; WHR: waist-to-hip ratio; TC: total
cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HOMA: homeostatic model assessment; IgE:
immunoglobulin E; hs-CRP: high-sensitivity C-reactive protein.
a). Variable is described in mean and standard deviation (data with normal distribution); one-way ANOVA.
b). Chi-square test.
c). Variable is described in median and interquartile range (data with skewed distribution); non-parametric Kruskal-Wallis test.
d). Combined P values with corresponding methods in a–c.
e). Linear regression analysis.
{P,0.05, compared with NGG;
{P,0.01, compared with NGG.
doi:10.1371/journal.pone.0028962.t001
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hypertension, BMI, TC, TG, hyperinsulinemia, hs-CRP, IgE,
tryptase, and chymase, only hs-CRP (OR: 3.814 [1.588–9.162,
95% CI], P=0.003) and IgE (OR: 3.367 [1.379–8.197, 95% CI],
P=0.008) remained significant risk factors for pre-diabetes,
whereas hypertension, WHR, BMI, TC, HOMA-b, HOMA-IR,
hs-CRP, and IgE became significant risk factors for diabetes
mellitus (Table S1).
Plasma hs-CRP, IgE, chymase, and tryptase as dependent
risk factors of pre-diabetes and diabetes mellitus
As discussed, the inflammatory biomarker hs-CRP associates
with diabetes mellitus [7,15]. When hs-CRP was considered as an
interaction variable with all other variables, we found that age, sex,
hypertension, WC (or WHR, or BMI), TG, HOMA-b, and IgE
were significant risk factors for pre-diabetes and diabetes mellitus,
compared with those from the NGG, in an ordinal logistic
regression model. In contrast, TC, HDL, LDL, HOMA-IR,
tryptase, and chymase were not significant risk factors for pre-
diabetes and diabetes mellitus. After adjusting these risk factors
using model three (Table 2), both age and sex lost their
significance as pre-diabetes and diabetes mellitus risk factors, but
other variables remained significant (Table 3). These observations
suggest that high plasma hs-CRP, in combination with high
plasma IgE, increased the risk of developing pre-diabetes and
diabetes mellitus with an odds ratio (OR) of 2.204 (1.020–4.759,
95% CI) before adjustment and an OR of 2.251 (1.037–4.885,
95% CI) after adjustment. We obtained different observations,
however, when we used a binary logistic regression model to
compare variables from the NGG to those from the PDG or the
DMG. Except age and sex, all tested variables (hypertension, WC,
WHR, BMI, TC, TG, low HDL, high LDL, hyperinsulinemia,
HOMA-b, HOMA-IR, IgE, tryptase, and chymase) were
significant risk factors for pre-diabetes, when interacting with
high plasma hs-CRP levels before or after adjustment (Table S2).
The same sets of variables also were significant risk factors for
diabetes mellitus before adjustment. But after adjustment, only
hypertension, WHR, TC, high LDL, HOMA-b, HOMA-IR, IgE,
and tryptase remained significant risk factors for diabetes mellitus
(Table S2).
Plasma IgE significantly increases in AMI patients, compared
with SAP patients or non-CHD patients [19]. In this Chinese
population, the interaction of plasma IgE level with hypertension,
WC, WHR, BMI, TG, HOMA-b, and chymase showed
significant changes in OR, compared with those from the NGG
before or after adjustment for all listed diabetes mellitus risk factors
(Table 4). This ordinal logistic model of two-variable interactions is
important, particularly under complicated circumstances. For
example, IgE levels impact the risk of pre-diabetes and diabetes
mellitus (OR: 1.674 [1.039–2.698, 95% CI], P=0.034), but
chymase alone did not affect the risk of pre-diabetes and diabetes
mellitus significantly (OR: 1.387 [0.858–2.244, 95% CI],
P=0.182) (Table 2). Interactions of chymase and IgE, however,
greatly increased the OR before adjustment (OR: 2.479 [1.079–
5.778, 95% CI], P=0.033) and after adjustment (OR: 2.594
[1.118–6.018, 95% CI], P=0.026) for all common diabetes
mellitus risk factors (Table 4), suggesting a dependent contribution
of plasma chymase and IgE to pre-diabetes and diabetes mellitus.
When we performed binary logistic regression analysis, we
found that interactions of high IgE with hypertension, WC, WHR,
TC, low HDL, high LDL, hyperinsulinemia, HOMA-b, HOMA-
IR, and chymase significantly increased the risk of having pre-
diabetes before and after adjustment, compared with those from
the NGG (Table S3). When we compared the variables between
Table 3. Infuence of interactions between CRP and different variables on the risk of developing pre-diabetes and diabetes mellitus
— ordinal logistic model.
Variable Before adjustment After adjustment (Model three)
OR (95.0% CI) Sig OR (95.0% CI) Sig
Age 1.828 (1.027–3.252) 0.040 1.636 (0.909–2.947) 0.101
Sex 1.868 (1.063–3.282) 0.030 1.695 (0.952–3.020) 0.073
Hypertension 2.552 (1.364–4.776) 0.003 2.397 (1.270–4.524) 0.007
WC 2.358 (1.273–4.367) 0.006 2.342 (1.256–4.364) 0.007
WHR 2.690 (1.207–5.998) 0.016 2.631 (1.178–5.876) 0.018
BMI 2.278 (1.202–4.317) 0.012 2.180 (1.135–4.184) 0.019
TC 1.424 (0.583–3.480) 0.438 1.447 (0.589–3.552) 0.420
TG 2.809 (1.335–5.909) 0.006 2.431 (1.118–5.285) 0.025
Lower HDL-C 1.096 (0.302–3.975) 0.889 1.072 (0.295–3.900) 0.916
Higher LDL-C 0.789 (0.185–3.373) 0.750 0.772 (0.180–3.308) 0.727
Hyperinsulinemia 1.829 (0.779–4.296) 0.166 1.550 (0.646–3.718) 0.326
HOMA-b index 4.091 (1.821–9.191) 0.001 4.222 (1.867–9.549) 0.001
HOMA-IR index 2.444 (0.994–6.008) 0.051 2.102 (0.835–5.294) 0.115
IgE 2.204 (1.020–4.759) 0.044 2.251 (1.037–4.885) 0.040
Tryptase 1.853 (0.859–4.000) 0.116 1.698 (0.776–3.713) 0.185
Chymase 2.031 (0.973–4.240) 0.059 1.892 (0.896–3.997) 0.094
OR: odds ratio; CI: confidence interval; WC: waist circumference; WHR: waist-to-hip ratio;
BMI: body-mass index; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HOMA: homeostatic
model assessment;
IgE: immunoglobulin E.
doi:10.1371/journal.pone.0028962.t003
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and hypertension, WC, WHR, BMI, TC, TG, HOMA-b, and
HOMA-IR were significant risk factors for diabetes mellitus. After
adjustment, while interactions between IgE and hypertension,
WHR, BMI, TC, HOMA-b, and HOMA-IR remained significant
risk factors for diabetes mellitus, the interactions of IgE with low
HDL, high LDL, chymase, and tryptase significantly increased the
risk of having diabetes mellitus (Table S3).
We made similar conclusions after analyzing interactions
between chymase and several other diabetes mellitus factors,
including hypertension, WC, WHR, TG, HOMA-b and HOMA-
IR (Table 5). Under all methods tested, however, plasma tryptase
alone did not correlate with plasma glucose levels (Table 1), nor
did it affect the risk of pre-diabetes and diabetes mellitus (OR:
1.283 [0.794–2.074, 95% CI], P=0.309) (Table 2). Its interactions
with hs-CRP (OR: 1.853 [0.859–4.000, 95% CI], P=0.116)
(Table 3), IgE (2.091 [0.946–4.625, 95% CI], P=0.068) (Table 4),
or chymase (OR: 1.220 [0.566–2.629], 95% CI], P=0.612)
(Table 5) did not significantly influence the risk of developing pre-
diabetes and diabetes mellitus. Interactions of plasma tryptase with
hypertension, WC, WHR, TC, TG, HOMA-b and HOMA-IR
did, however, increase the OR in an ordinal logistic model
significantly (Table 6).
When the NGG was compared independently with the PDG in
a binary logistic model, we found that interactions between
chymase and hypertension, WC, WHR, BMI, LDL, hyperinsu-
linemia, and tryptase were significant risk factors for pre-diabetes.
After adjustment, interactions between chymase and WC, WHR,
or HOMA-IR index affected the risk of pre-diabetes significantly
(Table S4). When the NGG was compared with the DMG in the
same model, interactions between chymase and hypertension,
WHR, BMI, HOMA-b, HOMA-IR, and tryptase were significant
risk factors for diabetes mellitus before and after adjustment (Table
S4). When interactions between tryptase and other variables were
considered in the binary logistic regression analysis, WC was the
only significant risk factor for pre-diabetes before adjustment, and
it lost its significance after adjustment (Table S5). When the NGG
was compared with the DMG, however, interactions between
tryptase and obesity variables (WC, WHR, and BMI), HOMA-b,
and HOMA-IR were significant risk factors for diabetes mellitus,
and BMI, HOMA-b, and HOMA-IR remained significant risk
factors for diabetes mellitus after adjustment (Table S5).
Discussion
Accumulating evidence indicates that age, sex, obesity,
hypertension, dyslipidemia, insulin resistance, decreased b-cell
sensitivity, hyperinsulinemia, HbA1c, and hs-CRP are related to
pre-diabetes and diabetes mellitus [25–36]. Inflammatory cyto-
kines are important to the pathogenesis of pre-diabetes and type 2
DM [37–39]. This study reveals that both IgE and chymase
correlate with glucose tolerance in humans. Interactions with other
diabetes risk factors greatly increased the impact of these mast-
cell–related molecules on pre-diabetes and diabetes mellitus.
Mast cell chymase and tryptase are important proteases that
have been implicated in cardiovascular diseases. Patients with
atherosclerosis and patients with abdominal aortic aneurysms
(AAAs) have elevated levels of these proteases [11,12,18].
Mechnistically, chymase contributes to angiogenesis, SMC
apoptosis, and mast cell cysteinyl cathepsin expression. Mast cells
lacking chymase or SMCs that are treated with chymase-deficient
mast cells demonstrate reduced cysteinyl cathepsin expression and
activties [11]. In contrast, mast cell tryptase contributes to EC
chemokine expression, monocyte and mast cell cysteinyl cathepsin
expression, leukocyte migration, and SMC apoptosis [12]. In
patients with small AAAs, plasma levels of these proteases associate
with abdominal aorta expansion rate, risks of later surgical repair,
or overall mortality. Although a direct participation of chymase or
Table 4. Infuence of interactions between IgE and different variables on the risk of developing pre-diabetes and diabetes mellitus
— ordinal logistic model.
Variable Before adjustment After adjustment (Model three)
OR (95.0% CI) Sig OR (95.0% CI) Sig
Age 1.292 (0.709–2.354) 0.402 1.409 (0.762–2.605) 0.275
Sex 1.648 (0.917–2.961) 0.095 1.795 (0.989–3.259) 0.055
Hypertension 2.830 (1.423–5.628) 0.003 2.776 (1.389–5.548) 0.004
WC 2.454 (1.275–4.724) 0.007 2.650 (1.364–5.148) 0.004
WHR 4.015 (1.773–9.093) 0.001 3.994 (1.760–9.063) 0.001
BMI 2.405 (1.246–4.643) 0.009 2.541 (1.303–4.954) 0.006
TC 1.416 (0.555–3.611) 0.467 1.777 (0.675–4.674) 0.244
TG 2.733 (1.362–5.486) 0.005 2.849 (1.403–5.788) 0.004
Lower HDL-C 1.607 (0.337–7.672) 0.552 1.272 (0.395–4.092) 0.687
Higher LDL-C 1.090 (0.161–7.377) 0.930 1.126 (0.165–7.669) 0.903
Hyperinsulinemia 1.642 (0.574–4.695) 0.355 1.633 (0.569–4.689) 0.362
HOMA-b index 4.350 (1.882–10.055) 0.001 5.768 (2.336–14.240) ,0.001
HOMA-IR index 2.672 (0.989–7.213) 0.053 2.738 (1.010–7.428) 0.048
Tryptase 2.091 (0.946–4.625) 0.068 2.167 (0.978–4.802) 0.057
Chymase 2.479 (1.079–5.778) 0.033 2.594 (1.118–6.018) 0.026
OR: odds ratio; CI: confidence interval; WC: waist circumference; WHR: waist-to-hip ratio;
BMI: body-mass index; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HOMA: homeostatic
model assessment.
doi:10.1371/journal.pone.0028962.t004
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experimental model, cysteinyl protease cathepsins — which are
indirectly regulated by chymase and tryptase [11,12] — have been
confirmed in diet-induced obesity and diabetes and in genetically-
generated obesity and diabetes. Mice deficient in cathepsin L or
cathepsin K, or treated with their selective inhibitors, are leaner
than control mice or have significantly improved glucose sensitivity
[40,41]. Both chymase and tryptase, therefore, may directly or
indirectly participate in the pathogenesis of diabetes mellitus — a
hypothesis that merits further investigation.
IgE often associates with allergic responses, but several small
human population studies indicated an association between serum
IgE levels and CHD. In the Helsinki Heart Study [42], a nested
case-control design and logistic regression analysis of 135 patients
Table 5. Infuence of interactions between chymase and different variables on the risk of developing pre-diabetes and diabetes
mellitus — ordinal logistic model.
Variable Before adjustment After adjustment (Model three)
OR (95.0% CI) Sig OR (95.0% CI) Sig
Age 1.328 (0.721–2.543) 0.351 1.291 (0.707–2.355) 0.406
Sex 1.614 (0.903–2.884) 0.106 1.542 (0.858–2.771) 0.148
Hypertension 2.388 (1.235–4.425) 0.009 2.281 (1.205–4.319) 0.011
WC 2.355 (1.168–4.479) 0.017 2.453 (1.213–4.962) 0.013
WHR 3.254 (1.351–7.838) 0.009 3.311 (1.374–7.983) 0.008
BMI 1.707 (0.864–3.371) 0.124 1.760 (0.889–3.483) 0.104
TC 2.206 (0.972–5.005) 0.058 2.275 (1.001–5.173) 0.050
TG 2.033 (1.006–4.110) 0.048 1.861 (0.913–3.795) 0.087
Lower HDL-C 1.490 (0.349–6.361) 0.590 1.507 (0.353–6.433) 0.579
Higher LDL-C 1.510 (0.316–7.209) 0.605 1.527 (0.320 –7.289) 0.595
Hyperinsulinemia 1.988 (0.763–5.184) 0.160 1.955 (0.749–5.100) 0.171
HOMA-b index 6.682 (2.267–16.996) ,0.001 7.078 (2.772–18.074) ,0.001
HOMA-IR index 4.033 (1.485–10.955) 0.006 3.969 (1.460–10.785) 0.007
Tryptase 1.220 (0.566–2.629) 0.612 1.223 (0.567–2.638) 0.608
OR: odds ratio; CI: confidence interval; WC: waist circumference; WHR: waist-to-hip ratio;
BMI: body-mass index; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HOMA: homeostatic
model assessment.
doi:10.1371/journal.pone.0028962.t005
Table 6. Infuence of interactions between tryptase and different variables on the risk of developing pre-diabetes and diabetes
mellitus — ordinal logistic model.
Variables Before adjustment After adjustment (Model three)
OR (95.0% CI) Sig OR (95.0% CI) Sig
Age 1.241 (0.691–2.228) 0.470 1.210 (0.668–2.193) 0.530
Sex 1.014 (0.557–1.846) 0.963 0.953 (0.518–1.753) 0.876
Hypertension 2.656 (1.357–5.198) 0.004 2.585 (1.320–5.061) 0.006
WC 2.157 (1.084–4.295) 0.029 2.165 (1.086–4.314) 0.028
WHR 3.642 (1.563–8.489) 0.003 3.696 (1.584–8.623) 0.002
BMI 1.560 (0.800–3.042) 0.192 1.508 (0.768–2.961) 0.232
TC 2.692 (1.104–6.564) 0.029 2.773 (1.135–6.775) 0.025
TG 2.351 (1.172–4.714) 0.016 2.158 (1.068–4.360) 0.032
Lower HDL-C 1.259 (0.391–4.049) 0.700 1.272 (0.395–4.092) 0.687
Higher LDL-C 1.312 (0.808–2.131) 0.272 1.289 (0.789–2.106) 0.310
Hyperinsulinemia 1.383 (0.543–3.523) 0.497 1.184 (0.453–3.095) 0.731
HOMA-b index 5.035 (2.094–12.107) ,0.001 5.768 (2.336–14.240) ,0.001
HOMA-IR index 2.747 (1.098–6.871) 0.031 2.406 (0.940–6.156) 0.067
OR: odds ratio; CI: confidence interval; WC: waist circumference; WHR: waist-to-hip ratio;
BMI: body-mass index; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HOMA: homeostatic
model assessment.
doi:10.1371/journal.pone.0028962.t006
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in CHD patients than in control subjects. In a group of 13 stable
patients from Turkey who underwent elective coronary artery
stenting, serum levels of IgE and hs-CRP reached their peaks at
the second and third post-procedure days, but returned to the
baseline at the end of the first month [43]. IgE, like hs-CRP, might
serve as a biomarker of inflammation in CHD, as shown in a
recent study from a group in Pakistan: 99 patients with a history of
ischemic heart disease (IHD) and established atherosclerosis on
angiography showed increased serum levels of oxidized LDL and
IgE, compared with those in 101 age-matched and sex-matched
healthy subjects without a known history of IHD [44]. We
demonstrated in two independent Chinese populations (982 and
240 patients, respectively) that plasma IgE levels were highest
among AMI patients, followed by UAP patients, SAP patients, and
non-CHD volunteers [19]. Although our original study [19] tested
the role of IgE on macrophages, SMCs, and ECs, one
conventional function of IgE is the activation of mast cells — a
cell type that plays critical roles in type 2 DM [10]. Our current
study demonstrates that plasma IgE levels strongly correlate with
glucose tolerance status (Table 1) and serves as a strong risk factor
for pre-diabetes and diabetes mellitus, either independently or in
their interactions with mast cell protease or many other diabetes
risk factors (Table 2, Table S1). Combining these clinical data and
our recent discoveries of IgE function in atherosclerosis [19], we
conjecture that IgE participates directly in the pathogenesis of
diabetes mellitus — a hypothesis that can be tested in animals in
the future.
But this study also has limitations. When we enrolled these
patients and volunteers, we did not exclude those who might have
asthma or other allergic diseases, which might affect blood IgE or
mast cell protease levels. Ideally, their circulating eosinophilic
leukocyte contents would be measured. A larger and more
complete population study therefore may be required to affirm
our observations. Nevertheless, this study provided the first
evidence that elevated plasma levels of mast cell proteases and
IgE may serve as important risk factors for human type 2 DM,
particularly when hs-CRP or other common diabetes mellitus risk
factors are considered. These mast cell proteases or IgE also may
serve as biomarkers for human type 2 DM.
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